HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?

This article was originally published in The Pink Sheet

Executive Summary

Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.

You may also be interested in...



Valeant Has Big Plans To Become A Big Pharma In Coming Year

The Canadian specialty pharma has been buying up companies left and right and has plans to continue in 2014, even possibly pursuing a merger of equals in an effort to more than double its market capitalization.

Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal

The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.

Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand

The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.

Topics

Related Companies

UsernamePublicRestriction

Register

RS139806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel